ArticleCureus2025
Changing Clinical Spectrum and Disease Progression in Young Patients With Bladder Cancer: A Retrospective Observational Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Complete Response to Intravesical BCG for High-Risk pT1 Bladder Cancer With Lymphovascular Invasion: A Case Report.Case reports in oncological medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Bladder cancer is a rare entity in young adults, and the course of the disease is not well defined. This study aims to analyze the clinical characteristics, risk factors, disease progression, and survival outcomes of bladder cancer patients aged 40 years or younger. Methods A retrospective review was conducted of 162 young bladder cancer patients treated from August 2017 to May 2024. Recurrence-free survival and overall survival were analyzed using Kaplan-Meier analysis. Results Of the 162 patients, 138 (85.2%) were male, with a mean age of 34.5 years. Key risk factors included tobacco use (80 patients, 49.4%) and occupational exposure to chemicals (50 patients, 30.9%). The predominant histology was urothelial carcinoma (159 patients, 98.1%). Muscle-invasive bladder cancer (MIBC) was observed in 42 patients (26.4%). Among patients with non-muscle-invasive bladder cancer (NMIBC), 61 (53.5%) had high-grade tumors. High-grade tumors and recurrence were frequent, with a mean recurrence-free survival of 3.7 years. Patients with muscle-invasive disease had poorer survival (mean 3.4 years) compared to those with non-muscle-invasive disease (mean 6 years). Conclusion Young bladder cancer patients exhibit a more aggressive disease course than reported in older cohorts. The findings underscore the importance of early detection, targeted treatment strategies, and tailored surveillance in young patients due to their unique risk factors and disease characteristics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.